MedTech Leadership

[anonymous]

Celine M is out and Michael B is in. Anyone know what happened?

 

[anonymous]

Celine M is out and Michael B is in. Anyone know what happened?

Seems like CSS was dissolved so they didn't need Celine anymore. Cerenovus is for sale, and BWI sales are collapsing due to the stroke-inducing Varipulse catheter. Also Mentor was transfered to Hani's Surgery group.

Also interesting to note that Shockwave & Abiomed are now under the direct control of Tim S. Those were taken away from Michael B.

Michael B's job is going to be to manage the divestiture of Cerenovus & then manage the future divestiture of BWI.

 

[anonymous]

Seems like CSS was dissolved so they didn't need Celine anymore. Cerenovus is for sale, and BWI sales are collapsing due to the stroke-inducing Varipulse catheter. Also Mentor was transfered to Hani's Surgery group.

Also interesting to note that Shockwave & Abiomed are now under the direct control of Tim S. Those were taken away from Michael B.

Michael B's job is going to be to manage the divestiture of Cerenovus & then manage the future divestiture of BWI.

Who's gonna buy BWI? The main value is the carto system but competitors are building their own mapping systems. RF needs to pivot beyond Afib to add value in a PFA world. Diagnostics are the only catheters of value post STSF. The engineers that know what they're doing have either left, retired, or moved to other divisions within JnJ. With the R&D budget cuts and culture change, there isn't much new innovation/IP that's worth buying. And lastly the company has been collapsing way before varipulse, growing at a smaller rate than the market. Then there's the culture in Irvine, Mexico, and Israel sites. That culture lead to drama, missed deadlines, and failed products in other JnJ companies.

 

[anonymous]

Who's gonna buy BWI? The main value is the carto system but competitors are building their own mapping systems. RF needs to pivot beyond Afib to add value in a PFA world. Diagnostics are the only catheters of value post STSF. The engineers that know what they're doing have either left, retired, or moved to other divisions within JnJ. With the R&D budget cuts and culture change, there isn't much new innovation/IP that's worth buying. And lastly the company has been collapsing way before varipulse, growing at a smaller rate than the market. Then there's the culture in Irvine, Mexico, and Israel sites. That culture lead to drama, missed deadlines, and failed products in other JnJ companies.

I'm sure some private equity group could buy BWI, the same way Platinum Equity acquired LifeScan from J&J. LifeScan also couldn't keep up with compeitors, similar to the situation BWI is in now. Private equity would just downsize & penny-pinch to extract wealth.

 

[anonymous]

Who's gonna buy BWI? The main value is the carto system but competitors are building their own mapping systems. RF needs to pivot beyond Afib to add value in a PFA world. Diagnostics are the only catheters of value post STSF. The engineers that know what they're doing have either left, retired, or moved to other divisions within JnJ. With the R&D budget cuts and culture change, there isn't much new innovation/IP that's worth buying. And lastly the company has been collapsing way before varipulse, growing at a smaller rate than the market. Then there's the culture in Irvine, Mexico, and Israel sites. That culture lead to drama, missed deadlines, and failed products in other JnJ companies.

Say more about the culture challenges.

Also in PFA world, what about PFA offerings in Biosense pipeline?

 

[anonymous]

Seems like CSS was dissolved so they didn't need Celine anymore. Cerenovus is for sale, and BWI sales are collapsing due to the stroke-inducing Varipulse catheter. Also Mentor was transfered to Hani's Surgery group.

Also interesting to note that Shockwave & Abiomed are now under the direct control of Tim S. Those were taken away from Michael B.

Michael B's job is going to be to manage the divestiture of Cerenovus & then manage the future divestiture of BWI.

Why will BWI be divested? Isn't BWI the market leader? I don't think Cerenovus will be sold. CNV leadership is very confident of gaining share with NPIs.

I'm not sure why Mentor was transfered to Surgery.

 

[anonymous]

I'm sure some private equity group could buy BWI, the same way Platinum Equity acquired LifeScan from J&J. LifeScan also couldn't keep up with compeitors, similar to the situation BWI is in now. Private equity would just downsize & penny-pinch to extract wealth.

BWI is a huge revenue driver. BWI will never be sold.

 

[anonymous]

BWI is a huge revenue driver. BWI will never be sold.

That's exactly what the geniuses at Cordis said while they were high sniffing their own farts.

 

[anonymous]

That's exactly what the geniuses at Cordis said while they were high sniffing their own farts.

Word

 

[anonymous]

BWI is a huge revenue driver. BWI will never be sold.

Sarcastic Troll

 

[anonymous]

Michael is going to lead BWI back to the powerhouse it once was. Unfortunately the DEI agenda has turned this division into an incompetent sorority of sales leaders, who have never sold a god damn thing in their lives. Michael brings common sense back to the organization, the Celine move is just the first of many moves to come. It’s on!

 

[anonymous]

Who's gonna buy BWI? The main value is the carto system but competitors are building their own mapping systems. RF needs to pivot beyond Afib to add value in a PFA world. Diagnostics are the only catheters of value post STSF. The engineers that know what they're doing have either left, retired, or moved to other divisions within JnJ. With the R&D budget cuts and culture change, there isn't much new innovation/IP that's worth buying. And lastly the company has been collapsing way before varipulse, growing at a smaller rate than the market. Then there's the culture in Irvine, Mexico, and Israel sites. That culture lead to drama, missed deadlines, and failed products in other JnJ companies.

Maybe J&J AI will innovate some new products for us.

 

[anonymous]

Did she just want to retire and cash out on that grandfathered pension in its last year?

 

[anonymous]

Did she just want to retire and cash out on that grandfathered pension in its last year?

No way, she was not looking to retire. This must have been unexpected. That pension must be massive though!

 

[anonymous]

Maybe J&J AI will innovate some new products for us.

Hahahahahaha.

 

[anonymous]

Seems like CSS was dissolved so they didn't need Celine anymore. Cerenovus is for sale, and BWI sales are collapsing due to the stroke-inducing Varipulse catheter. Also Mentor was transfered to Hani's Surgery group.

Also interesting to note that Shockwave & Abiomed are now under the direct control of Tim S. Those were taken away from Michael B.

Michael B's job is going to be to manage the divestiture of Cerenovus & then manage the future divestiture of BWI.

 

[anonymous]

Then manage his own golden parachute.

 

[anonymous]

No way, she was not looking to retire. This must have been unexpected. That pension must be massive though!

Is she the person that said that English is not her native language so she does not know how to tell a lie in English?

 

[anonymous]

No way, she was not looking to retire. This must have been unexpected. That pension must be massive though!

She can return to her singing career now.

 

[anonymous]

Timmy is trying not to get Ashley’ed. MedTech is a quagmire that needs a huge transformation. Sell the losers, beef up the winners. Easy Peasy.